A Phase 2 interventional study of Selexipag and Placebo in Sarcoidosis-associated Pulmonary Hypertension, sponsored by Actelion. Terminated at 38 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.
Among the 115 studies in Sarcoidosis with a site in United States, this one is the 47th largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2021, is one of 26 in phase 2, and was the 82nd registered.
271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.
Browse Sarcoidosis studies →23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Priovant Therapeutics, Inc. · Sites in United States, Australia, United Kingdom
Ages 18+
University of Pennsylvania · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Sarcoidosis studies recruiting now, 30 (75%) set no upper age limit and 1 (3%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 37 · Phase 3 10 · Phase 4 12
First in 1978; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 50 across 145 interventional studies indexed under Sarcoidosis.
Median enrollment 16 across the 69 interventional studies, 200 across the 46 observational. Of the 72 that completed or were terminated, 30 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 3 studies filed under Sarcoidosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcoidosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03593759Phase 3Ottawa Heart Institute Research CorporationCardiac Sarcoidosis Randomized Trial | 2026-12 |
| NCT03621553University of Texas Southwestern Medical CenterVitamin D Homeostasis in Sarcoidosis | 2026-12 |
| NCT07159074Duke UniversityRepurposing Tilmanocept for Cardiac Sarcoidosis | 2026-12-01 |
| NCT05171478Johns Hopkins UniversityFull-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens | 2026-12-08 |
| NCT06510894University of PennsylvaniaDiagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 115 studies in Sarcoidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate several cardiovascular and respiratory diseases. Sarcoidosis is a multisystemic disorder that is characterized by non-caseating granulomas which are present in multiple tissues, particularly in the lung and lymphatic system. Severe untreated pulmonary hypertension (PH) carries a poor prognosis and is associated with higher mortality in participants with interstitial lung diseases and sarcoidosis. While there is no approved treatment for SAPH, PH-specific treatments are frequently used. Selexipag is a selective, orally available and long-acting non-prostanoid agonist of the prostacyclin receptor (prostacyclin [IP] receptor) for the treatment of patients with PAH. The rationale for this study is based on the unmet medical need for new therapeutic options for patients with SAPH and is supported by the established efficacy and safety of selexipag in the PAH indication, the shared pathomechanism between SAPH and PAH, and the available data on the efficacy and safety of PH-specific therapies in SAPH. This study consists of screening period, main observation period and double blind extension period and safety follow-up period. The duration of individual participation in the study will be different for each individual participant (between approximately 15 months and up to approximately 3.5 years) and will depend on the time of each participant's individual date of entering the study and the total recruitment time. The efficacy assessments include right heart catheterization (RHC), assessment of exercise capacity, dyspnea, pulmonary function tests, etc. Safety and tolerability will be evaluated throughout the study and includes review of concomitant medications and adverse events (AEs), clinical laboratory tests, 12-lead electrocardiogram (ECG), vital signs, physical examination, and pregnancy testing.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) twice daily/once daily. Dosing frequency will be twice daily, except for participants with moderate hepatic impairment (Child-Pugh Class B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention once daily. The dose will be up-titrated by the investigator/delegate in 200 μg twice daily/once daily increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg twice daily/once daily.
Drug: Selexipag
The comparator will be administered similarly to the experimental intervention.
Drug: Placebo
Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
Also known as: JNJ-678896049; ACT-293987
Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
Pulmonary Vascular Resistance (PVR) up to Week 26
PVR represents the resistance against which the right ventricle needs to pump. PVR was determined by right heart catheterization (RHC). It was measured as the ratio of the PVR value post-treatment initiation up to Week 26 (post) versus the PVR value pre-treatment initiation at baseline (pre), expressed as a percentage of baseline value. The baseline reference value for PVR was based on the last RHC performed prior to study intervention initiation. PVR was calculated as 80\*(mean pulmonary arterial pressure - pulmonary artery wedge pressure) divided by cardiac output. As specified in the statistical analysis plan, data was not planned to be summarized for this outcome measure and only individual participant wise data was collected.
Time frame: Baseline up to Week 26
| Milestone | Selexipag 200 Micrograms (mcg) | Placebo |
|---|---|---|
| Started | 6 | 4 |
| Completed | 0 | 0 |
| Not completed | 6 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Study terminated by sponsor | 5 | 3 |
| Withdrew: Adverse event | 0 | 1 |
PVR represents the resistance against which the right ventricle needs to pump. PVR was determined by right heart catheterization (RHC). It was measured as the ratio of the PVR value post-treatment initiation up to Week 26 (post) versus the PVR value pre-treatment initiation at baseline (pre), expressed as a percentage of baseline value. The baseline reference value for PVR was based on the last RHC performed prior to study intervention initiation. PVR was calculated as 80\*(mean pulmonary arterial pressure - pulmonary artery wedge pressure) divided by cardiac output. As specified in the statistical analysis plan, data was not planned to be summarized for this outcome measure and only individual participant wise data was collected.
| percentage of baseline PVR | Selexipag 200 Micrograms (mcg) | Placebo |
|---|---|---|
| Participant 1 | — | 89.0 |
| Participant 2 | — | 201 |
| Participant 3 | — | 56 |
| Participant 4 | 88 | — |
| Participant 5 | 100 | — |
| Participant 6 | 47.0 | — |
| Participant 7 | 82.0 | — |
| Participant 8 | 86.0 | — |
Collected over From Day 1 up to 456 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag 200 Micrograms (mcg) | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Placebo | 0/4 (0%) | 3/4 (75%) | 3/4 (75%) |
| Event | Selexipag 200 Micrograms (mcg) | Placebo |
|---|---|---|
| Angina PectorisCardiac disorders | 0/6 | 1/4 |
| Pneumonia AspirationInfections and infestations | 0/6 | 1/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/6 | 1/4 |
| Pulmonary HypertensionRespiratory, thoracic and mediastinal disorders | 0/6 | 1/4 |
| Cardiac FailureCardiac disorders | 1/6 | 0/4 |
| PneumoniaInfections and infestations | 1/6 | 0/4 |
| Urinary Tract InfectionInfections and infestations | 1/6 | 0/4 |
| FallInjury, poisoning and procedural complications | 1/6 | 0/4 |
| Event | Selexipag 200 Micrograms (mcg) | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 5/6 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 4/6 | 1/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/6 | 0/4 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 4/6 | 0/4 |
| Covid-19Infections and infestations | 3/6 | 0/4 |
| Pain in JawMusculoskeletal and connective tissue disorders | 3/6 | 0/4 |
| NauseaGastrointestinal disorders | 2/6 | 0/4 |
| MigraineNervous system disorders | 2/6 | 0/4 |
| MalaiseGeneral disorders | 0/6 | 1/4 |
| Lower Respiratory Tract InfectionInfections and infestations | 0/6 | 1/4 |
| Age, Categorical(Participants) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 0 | 4 |
| >=65 years | 2 | 4 | 6 |
| Age, Continuous(years) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| Mean | 55 ± 14.53 | 68.5 ± 2.38 | 60.4 ± 12.95 |
| Sex: Female, Male(Participants) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 4 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 3 | 8 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Selexipag 200 Micrograms (mcg) | Placebo | Total |
|---|---|---|---|
| France | 0 | 1 | 1 |
| Germany | 4 | 0 | 4 |
| Spain | 1 | 1 | 2 |
| United Kingdom | 1 | 0 | 1 |
| United States | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Actelion is a Janssen pharmaceutical company of Johnson \& Johnson. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2021 to primary completion in Apr 2023, 25 months.
Results were first posted in May 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag